Tag Archives: MACK

Hot Blue Chip Stocks To Watch For 2019

Shutterstock

When blue chips get too popular – like the five I’m going to show you today – these “safe stocks” can actually be dangerous to continue holding in your portfolio.

The problem with blue-chip stocks? Call it the “Curse of the Dow.” The Curse says a stock that joins the Dow Jones Industrial Average will essentially hit a wall, underperforming in the ensuing months compared to how it performed before ascension. It’s not perfect, but it’s close – since 1999, 15 of 16 stocks that have joined the Dow have averaged 1% gains over the next six months, but averaged 11% gains in the six months before inclusion.

Why? There are a few factors, but one of the most prevailing is that by the point a stock has joined the Dow, it’s typically nearing the end of its growth ramp and reaching the slower-growth “mature” part of the business cycle.

Hot Blue Chip Stocks To Watch For 2019: Ormat Technologies, Inc.(ORA)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Orange (EPA:ORA) received a €16.50 ($19.19) price target from Credit Suisse Group in a research note issued to investors on Wednesday. The firm currently has a “buy” rating on the stock. Credit Suisse Group’s price target indicates a potential upside of 17.61% from the stock’s previous close.

  • [By Shane Hupp]

    JPMorgan Chase lowered shares of Ormat Technologies (NYSE:ORA) from an overweight rating to a neutral rating in a research note issued to investors on Monday, MarketBeat.com reports. They currently have $62.00 price target on the energy company’s stock.

  • [By Shane Hupp]

    Ormat Technologies (NYSE:ORA) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

  • [By Max Byerly]

    JPMorgan Chase & Co. lessened its stake in shares of Ormat Technologies, Inc. (NYSE:ORA) by 9.3% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 225,381 shares of the energy company’s stock after selling 23,000 shares during the period. JPMorgan Chase & Co.’s holdings in Ormat Technologies were worth $12,708,000 at the end of the most recent reporting period.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Ormat Technologies (ORA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Scott Levine]

    When talk around the water cooler turns to energy investments, it’s oil and gas companies that represent the usual suspects. Renewable energy companies like Vestas Wind Systems (NASDAQOTH:VWDRY), First Solar (NASDAQ:FSLR), and Ormat Technologies (NYSE:ORA) — companies whose names are far less recognizable than those like ExxonMobil and Chevron — may not be on most investors’ radars. However, there are certainly reasons to believe that they should be.

Hot Blue Chip Stocks To Watch For 2019: Shoe Carnival, Inc.(SCVL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday morning, the consumer discretionary shares surged 0.30 percent. Meanwhile, top gainers in the sector included Foot Locker, Inc. (NYSE: FL), up 13 percent, and Shoe Carnival, Inc. (NASDAQ: SCVL) up 14 percent.

  • [By Stephan Byrd]

    Shoe Carnival (NASDAQ:SCVL) – Equities researchers at Wedbush increased their Q2 2019 earnings per share (EPS) estimates for Shoe Carnival in a research note issued to investors on Friday, May 25th. Wedbush analyst C. Svezia now forecasts that the company will earn $0.55 per share for the quarter, up from their previous forecast of $0.45. Wedbush also issued estimates for Shoe Carnival’s Q3 2019 earnings at $0.64 EPS and FY2020 earnings at $2.24 EPS.

  • [By Logan Wallace]

    Media headlines about Shoe Carnival (NASDAQ:SCVL) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Shoe Carnival earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.6045751862708 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

  • [By Max Byerly]

    Shoe Carnival, Inc. (NASDAQ:SCVL) announced a quarterly dividend on Monday, June 18th, NASDAQ reports. Stockholders of record on Monday, July 9th will be paid a dividend of 0.08 per share on Friday, July 27th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Friday, July 6th.

Hot Blue Chip Stocks To Watch For 2019: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Chris Lange]

    Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) shares were absolutely crushed on Monday after the firm gave an update from its midstage pancreatic cancer study. Specifically, the top-line results come from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141 (istiratumab) to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
    Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
    Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
    Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
    Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
    vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
    Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
    Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
    Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
    GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
    Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market

  • [By Max Byerly]

    Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod (finance.yahoo.com) Merrimack Fails Phase 2 Pancreatic Cancer Study, But Opportunity Remains (seekingalpha.com) Merrimack Pharmaceuticals’ (MACK) “Hold” Rating Reaffirmed at Robert W. Baird (americanbankingnews.com) Merrimack Crashes as Phase II Pancreatic Cancer Study Fails (zacks.com) MM-141 (benzinga.com)

    Several equities analysts have commented on MACK shares. Zacks Investment Research raised Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a research report on Wednesday, April 25th. JPMorgan Chase & Co. downgraded Merrimack Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Monday. Robert W. Baird cut their price objective on Merrimack Pharmaceuticals from $12.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, ValuEngine raised Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.

Hot Blue Chip Stocks To Watch For 2019: Veeco Instruments Inc.(VECO)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Shares of Veeco Instruments Inc. (NASDAQ:VECO) have been assigned an average recommendation of “Hold” from the six analysts that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company.

  • [By Lisa Levin] Gainers
    Integrated Media Technology Limited (NASDAQ: IMTE) rose 30.8 percent to $22.00 in pre-market trading after declining 18.63 percent on Monday.
    Nevsun Resources Ltd. (NYSE: NSU) rose 14.5 percent to $3.40 in pre-market trading after Lundin Mining Corporation and Euro Sun Mining Inc. proposed to acquire Nevsun Resources for around C$1.5 billion.
    Sharing Economy International Inc. (NASDAQ: SEII) rose 15.2 percent to $4.25 in pre-market trading after the company disclosed that it entered into a license agreement with Ecrent Capital Holdings Limited.
    Veeco Instruments Inc. (NASDAQ: VECO) shares rose 14.1 percent to $19.50 in pre-market trading after reporting stronger-than-expected earnings for its first quarter.
    Impinj, Inc. (NASDAQ: PI) rose 13.4 percent to $15.40 in pre-market trading after reporting Q1 results.
    SandRidge Energy, Inc. (NYSE: SD) shares rose 13.2 percent to $16.45 in pre-market trading following Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) rose 12.6 percent to $4.55 in pre-market trading after jumping 171.14 percent on Monday.
    Crocs, Inc. (NASDAQ: CROX) shares rose 10 percent to $16.66 in pre-market trading after the company reported better-than-expected earnings for its first quarter and issued strong sales forecast for the second quarter.
    Pareteum Corporation (NASDAQ: TEUM) rose 9.7 percent to $3.05 in pre-market trading after announcing Q1 results.
    Dean Foods Company (NYSE: DF) rose 8 percent to $9.00 in pre-market trading after reporting upbeat Q1 earnings.
    Fiesta Restaurant Group, Inc. (NASDAQ: FRGI) rose 7.3 percent to $23.45 in pre-market trading following Q1 results.
    IAMGOLD Corporation (NYSE: IAG) rose 7.1 percent to $6.09 in pre-market trading after reporting upbeat Q1 earnings.
    TC PipeLines, LP (NYSE: TCP) rose 6.4 percent to $27 in pre-market trading after gaining 2.08 percent on Monday.
    Carrols Restaurant Group, Inc. (NASDAQ: TAST) rose 6.3 percent to $11.75 in pre-market trading fol
  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Veeco Instruments (VECO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Blue Chip Stocks To Watch For 2019: Liquor Stores N.A. Ltd. (LQSIF)

Advisors’ Opinion:

  • [By ]

    British Columbia and Alberta have chosen a different strategy where retail sales will be allowed through both public and private stores, similar to its current setup for liquor retail in the provinces. Retailers will have to get their supply of cannabis from the government’s wholesale distribution system, similar to how it works for alcohol now. The government will control online cannabis sales exclusively Our take: British Columbia also announced that physical retailing of cannabis and liquor will have to be separate, meaning stores cannot sell both products. This rule has an impact on existing liquor retailers aiming to convert some of their stores to sell cannabis. Aurora invested in Liquor Stores (renamed to Alcanna (OTCPK:LQSIF)) which has been struggling for years in the liquor business. Other pharmacy chains will also participate in the RFP as we have seen in Loblaw’s recent win in Newfoundland and Labrador. We think for many cannabis companies the path to winning those retail licenses will be a challenging one with the competition from multiple sources. The licenses will be hotly contested given that B.C. is the largest market to allow private retailing, leaving us cautious on those companies betting big on winning those contracts. The likely outcome is that a large number of companies will each win fewer contracts.

  • [By ]

    It also holds just under 20 percent share of Liquor Stores N.A. (OTCPK:LQSIF) and over 17 percent of Radient Technologies Inc. (OTC:RDDTF). Aurora has other holdings as well.

Top Gold Stocks To Buy For 2019

April 6, 2017: Markets opened higher again Thursday and gathered strength until early afternoon when all three major indexes gave back most of the day’s gains. Energy and real estate led the S&P sectors, while telecom lagged. WTI crude oil for May delivery settled at $51.70 a barrel, up 1.1% on the day. June gold added 0.4% on the day to settle at $1,253.30. Equities were headed for a modestly higher close shortly before the bell as the DJIA traded up 0.05% for the day, the S&P 500 traded up 0.16%, and the Nasdaq Composite traded up 0.16%.

The DJIA stock posting the largest daily percentage gain ahead of the close Thursday was Caterpillar Inc. (NYSE: CAT) which traded up 1.66% at $95.80. The stock’s 52-week range is $57.05 to $93.98. Volume was about 20% below the daily average of around 5.3 million shares. The heavy equipment maker had no specific news.

Exxon Mobil Corp. (NYSE: XOM) traded up 0.56% at $83.00. The stock’s 52-week range is $80.31 to $95.55. Volume was about half the daily average of around 13 million shares. The company had no specific news.

Top Gold Stocks To Buy For 2019: Cooper Companies, Inc. (COO)

Advisors’ Opinion:

  • [By Stephan Byrd]

    The Cooper Companies (NYSE:COO) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Cooper Companies has recently acquired the assets of The LifeGlobal Group and its affiliates, bolstering its foothold in the in-vitro fertilization (IVF) devices market. Meanwhile, the CooperVision business has been delivering impressive results. A raised guidance for fiscal 2018 looks promising. Notably, Cooper Companies completed the acquisition of Paragon Vision Sciences. This added a leading ortho-k technology to the company’s lens portfolio. Considering the outstanding performance of the stock, we expect Cooper Companies to scale higher in the coming quarters. On the flipside, intense competition in the contact lens space will continue to build pricing pressure. Additionally, escalating debt levels and foreign exchange vulnerability are likely to mar the company’s bottom line. Also, the slashed revenue guidance for fiscal 2018 in CSI segment is discouraging. Cooper has underperformed its industry in a year’s time.”

  • [By Stephan Byrd]

    Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

    Get The Cooper Companies alerts:

    Homeownership Is Dead. The Future Lies in Public Housing. (inthesetimes.com) Form 4 COOPER COMPANIES INC For: May 01 Filed by: White Albert G III (streetinsider.com) Form 4 COOPER COMPANIES INC For: May 01 Filed by: Andrews Brian G (streetinsider.com) North Carolina Medicaid Scandal Broadens on Dem. Gov. Coopers Watch (spectator.org) Head to Head Contrast: STAAR Surgical (STAA) and The Cooper Companies (COO) (americanbankingnews.com)

    A number of research firms recently commented on COO. Goldman Sachs began coverage on shares of The Cooper Companies in a research note on Wednesday, April 4th. They issued a “neutral” rating and a $231.00 price objective for the company. Zacks Investment Research lowered shares of The Cooper Companies from a “buy” rating to a “hold” rating in a research note on Monday, January 8th. TheStreet lowered shares of The Cooper Companies from a “b” rating to a “c” rating in a research note on Thursday, March 8th. Oppenheimer set a $265.00 price objective on shares of The Cooper Companies and gave the stock a “hold” rating in a research note on Friday, March 9th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $280.00 price objective (up previously from $277.00) on shares of The Cooper Companies in a research note on Friday, March 9th. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The Cooper Companies currently has an average rating of “Hold” and a consensus price target of $264.18.

  • [By Garrett Baldwin]

    Goldman Sachs Group Inc. (NYSE: GS) chief economist Jan Hatzius has a message for the markets. Hatzius said in a research note on Monday that U.S. GDP has likely peaked. “The current pace is probably as good as it gets because we expect the impulse from financial conditions to gradually turn more negative,” Hatzius said.
    The European Union slapped America with roughly $3.3 billion in tariffs on U.S. goods. The tariffs, which are in retaliation to the Trump administration’s recent steel and aluminum tariffs on the EU, will go into effect in July. They specifically target products like cigarettes, whiskey, denim, and orange juice.
    Stocks to Watch Today: AVGO, AGN, GOOGL, TSLA
    Broadcom Ltd.(Nasdaq: AVGO) leads a busy day of earnings reports. Wall Street anticipates the firm will report earnings per share of $4.77 on top of $5.00 billion in revenue. Uncertainty still remains on whether the company will be able to purchase industry rival Qualcomm Inc.(Nasdaq: QCOM) in a deal that would be the largest technology merger in the history of the markets.
    Shares of Alphabet Inc. (Nasdaq: GOOGL) are under pressure due to more regulatory scrutiny by the European Union. Shares were off slightly this morning as investors digested a report from The Financial Times indicating the EU will hit the firm with a antitrust fine.
    Tesla Inc. (Nasdaq: TSLA) stock popped nearly 10% Wednesday, crushing short sellers of the stock. Investors betting against the stock lost a collective $1 billion on paper yesterday, according to S3 Partners. This week, founder Elon Musk won a battle to maintain his roles as both CEO and chair. He also provided a boost of optimism to TSLA stock over production expectations for the Model 3 vehicle.
    Allergan Inc. (NYSE: AGN) shares are up 2.4% thanks to its latest activist investor. Billionaire investor Carl Icahn purchased a small stake in the drug maker at a time when other activist investors are pushing for strategic changes by the company.

  • [By Max Byerly]

    The Cooper Companies, Inc. (NYSE:COO) has been given an average rating of “Hold” by the sixteen ratings firms that are presently covering the firm, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $264.73.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was The Cooper Companies, Inc. (NYSE: COO) which traded down 3.7% at $242.09. The stocks 52-week range is $192.24 to $260.26. Volume was nearly 1 million compared to the daily average volume of less than half a million.

Top Gold Stocks To Buy For 2019: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
    Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
    Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
    Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
    Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
    vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
    Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
    Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
    Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
    GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
    Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market

  • [By Chris Lange]

    Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) shares were absolutely crushed on Monday after the firm gave an update from its midstage pancreatic cancer study. Specifically, the top-line results come from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141 (istiratumab) to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer.

  • [By Max Byerly]

    Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod (finance.yahoo.com) Merrimack Fails Phase 2 Pancreatic Cancer Study, But Opportunity Remains (seekingalpha.com) Merrimack Pharmaceuticals’ (MACK) “Hold” Rating Reaffirmed at Robert W. Baird (americanbankingnews.com) Merrimack Crashes as Phase II Pancreatic Cancer Study Fails (zacks.com) MM-141 (benzinga.com)

    Several equities analysts have commented on MACK shares. Zacks Investment Research raised Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a research report on Wednesday, April 25th. JPMorgan Chase & Co. downgraded Merrimack Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Monday. Robert W. Baird cut their price objective on Merrimack Pharmaceuticals from $12.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, ValuEngine raised Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.

  • [By Shane Hupp]

    Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT (finance.yahoo.com) Investors Purchase High Volume of Merrimack Pharmaceuticals Call Options (MACK) (americanbankingnews.com) Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 (finance.yahoo.com) Merrimack Pharmaceuticals (MACK) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS (americanbankingnews.com) Merrimack Pharmaceuticals’ (MACK) CEO Richard Peters on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)

    A number of equities analysts have issued reports on MACK shares. Robert W. Baird reiterated a “hold” rating and issued a $12.00 price objective on shares of Merrimack Pharmaceuticals in a report on Thursday, March 15th. Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a report on Wednesday, April 25th.

Top Gold Stocks To Buy For 2019: Mercantile Bank Corporation(MBWM)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Shares of Mercantile Bank Co. (NASDAQ:MBWM) have been given a consensus recommendation of “Hold” by the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $36.33.

  • [By Stephan Byrd]

    Capstar Financial (NASDAQ: CSTR) and Mercantile Bank (NASDAQ:MBWM) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Mercantile Bank (MBWM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Royal Bank of Canada raised its position in Mercantile Bank Corp. (NASDAQ:MBWM) by 9.6% during the 1st quarter, HoldingsChannel.com reports. The firm owned 220,880 shares of the financial services provider’s stock after purchasing an additional 19,273 shares during the period. Royal Bank of Canada’s holdings in Mercantile Bank were worth $7,344,000 as of its most recent SEC filing.

Top Gold Stocks To Buy For 2019: OpenTable Inc.(OPEN)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Open Platform (CURRENCY:OPEN) traded 2.5% higher against the US dollar during the one day period ending at 20:00 PM Eastern on June 30th. Open Platform has a total market cap of $0.00 and $189,463.00 worth of Open Platform was traded on exchanges in the last day. One Open Platform token can now be bought for approximately $0.0789 or 0.00001235 BTC on popular cryptocurrency exchanges. During the last seven days, Open Platform has traded down 28.6% against the US dollar.

  • [By Max Byerly]

    Open Platform (CURRENCY:OPEN) traded down 8.2% against the dollar during the 24 hour period ending at 9:00 AM ET on June 25th. Open Platform has a total market capitalization of $0.00 and $1.10 million worth of Open Platform was traded on exchanges in the last 24 hours. Over the last week, Open Platform has traded 33.4% lower against the dollar. One Open Platform token can currently be purchased for approximately $0.0923 or 0.00001514 BTC on popular exchanges.

Top Gold Stocks To Buy For 2019: Mattersight Corporation(MATR)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Genprex, Inc. (NASDAQ: GNPX) shares gained 86.76 percent to close at $11.00 on Thursday.
    Comstock Resources, Inc. (NYSE: CRK) shares climbed 47.06 percent to close at $7.00 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes.
    Ceridian HCM Holding Inc. (NASDAQ: CDAY) gained 41.86 percent to close at $31.21.
    MarineMax, Inc. (NYSE: HZO) shares rose 26.5 percent to close at $22.20 as the company posted upbeat Q2 results and raised its FY18 outlook.
    Concord Medical Services Holdings Limited (NYSE: CCM) jumped 24.92 percent to close at $4.06.
    Mattersight Corporation (NASDAQ: MATR) shares climbed 23.26 percent to close at $2.65 after the company agreed to be purchased by NICE Ltd.
    Chipotle Mexican Grill, Inc. (NYSE: CMG) rose 24.44 percent to close at $422.50 as the company reported stronger-than-expected results for its first quarter on Wednesday.
    Ultra Clean Holdings, Inc. (NASDAQ: UCTT) gained 17.75 percent to close at $18.64 following upbeat Q1 earnings.
    PCM, Inc. (NASDAQ: PCMI) rose 16.59 percent to close at $12.30 following Q1 results.
    Zymeworks Inc. (NASDAQ: ZYME) rose 16.06 percent to close at $15.25.
    Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares climbed 14.5 percent to close at $121.42 as the company posted reported Q1 beat And raised FY18 outlook.
    Advanced Micro Devices, Inc. (NASDAQ: AMD) shares gained 13.7 percent to close at $11.04 as the company reported upbeat results for its first quarter.
    Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 13.21 percent to close at $3.00 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression.
    O'Reilly Automotive, Inc. (NASDAQ: ORLY) jumped 13.06 percent to close at $257.40 following upbeat Q1 profit.
    BioTelemetry,
  • [By Lisa Levin] Gainers
    Comstock Resources, Inc. (NYSE: CRK) shares shot up 52 percent to $7.235 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes.
    MarineMax, Inc. (NYSE: HZO) shares gained 24.2 percent to $21.80 as the company posted upbeat Q2 results and raised its FY18 outlook.
    Mattersight Corporation (NASDAQ: MATR) shares rose 22 percent to $2.625 after the company agreed to be purchased by NICE Ltd.
    Chipotle Mexican Grill, Inc. (NYSE: CMG) jumped 21.3 percent to $411.871 as the company reported stronger-than-expected results for its first quarter on Wednesday.
    Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 17 percent to $3.10 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression.
    Ultra Clean Holdings, Inc. (NASDAQ: UCTT) rose 15.9 percent to $18.34 following upbeat Q1 earnings.
    PCM, Inc. (NASDAQ: PCMI) gained 15.6 percent to $12.20 following Q1 results.
    O'Reilly Automotive, Inc. (NASDAQ: ORLY) surged 14.4 percent to $260.3901 following upbeat Q1 profit.
    Concord Medical Services Holdings Limited (NYSE: CCM) gained 13.8 percent to $3.70.
    Penn National Gaming, Inc. (NASDAQ: PENN) rose 13.5 percent to $29.815 after reporting strong Q1 results.
    BioTelemetry, Inc. (NASDAQ: BEAT) rose 13.5 percent to $38.30 as the company reported stronger-than-expected earnings for its first quarter.
    Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 13.1 percent to $10.985 as the company reported upbeat results for its first quarter.
    SJW Group (NYSE: SJW) shares gained 11.8 percent to $63.59 following Q1 results. California Water Service Group made an offer for SJW.
    Churchill Downs Incorporated (NASDAQ: CHDN) climbed 9.8 percent to $278.40 following Q1 results.
    CYS Investments, Inc. (NYSE: CYS)
  • [By Stephan Byrd]

    Mattersight (NASDAQ: MATR) and Simulations Plus (NASDAQ:SLP) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

  • [By Shane Hupp]

    Ebix (NASDAQ: EBIX) and Mattersight (NASDAQ:MATR) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Top 10 Low Price Stocks To Buy For 2019

Wal-Mart (NYSE:WMT) has made a lot of efforts in pricing its goods attractively over the past months. This allowed for strong traffic growth, which resulted in positive comps for the company. Subsequently, Wal-Mart’s shares have been performing much better than those of its peers, which are reporting worse comp sales. Due to Wal-Mart’s power when it comes to discussing prices with its suppliers, the company is able to price its goods attractively whilst generating strong margins, which, in turn, means that the earnings power of Wal-Mart remains high (despite the low prices Wal-Mart offers its goods at), which makes Wal-Mart a compelling retail investment.

Top 10 Low Price Stocks To Buy For 2019: NovoCure Limited(NVCR)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on NovoCure (NVCR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Brian Feroldi]

    After the company reported first-quarter results, shares of NovoCure (NASDAQ:NVCR), a medical device company focused on cancer, jumped as much as 10% in afternoon trading on Thursday. Shares closed the day up more than 9%.

  • [By Chris Lange]

    Novocure Ltd. (NASDAQ: NVCR) announced results from its Phase 3 INNOVATE trial of TTFields in platinum-resistant ovarian cancer. There were no major surprises, except study size is larger than some investors expected, which is not concerning. INNOVATE-3 is set to start later this year and as previously announced will enroll patients with recurrent platinum-resistant ovarian cancer.

  • [By Todd Campbell, Sean Williams, and Brian Feroldi]

    There have been more stock market pops and drops lately and that might have you wondering what healthcare stocks can be bought to take advantage of this volatility. Buying healthcare stocks during periods of volatility can be smart because demand for healthcare products and services usually isn’t discretionary. However, that doesn’t necessarily mean it makes sense to buy every healthcare stock out there. To find out what healthcare stocks it might make sense to buy this month, we asked top Motley Fool investors what companies are on their radar. In their view,Teva Pharmaceutical Industries (NYSE:TEVA), Novacure (NASDAQ:NVCR), and Galapagos (NASDAQ:GLPG)should be at the top of your idea list right now. Read on to find out why.

  • [By Lee Jackson]

    This stock has been on a roll and looks ready to break out. NovoCure Ltd. (NASDAQ: NVCR) develops and commercializes treatments for solid tumor cancer therapy called the tumor treating fields (TTFields). Its markets its proprietary TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.

  • [By Ethan Ryder]

    NovoCure (NASDAQ:NVCR) Director Gabriel Leung sold 80,000 shares of the firm’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $28.83, for a total value of $2,306,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Top 10 Low Price Stocks To Buy For 2019: MFS Charter Income Trust(MCR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Macro (CURRENCY:MCR) traded flat against the U.S. dollar during the 24 hour period ending at 20:00 PM E.T. on May 30th. During the last seven days, Macro has traded down 6% against the U.S. dollar. Macro has a total market cap of $0.00 and approximately $0.00 worth of Macro was traded on exchanges in the last day. One Macro token can now be bought for about $0.17 or 0.00002339 BTC on popular cryptocurrency exchanges.

Top 10 Low Price Stocks To Buy For 2019: Xerium Technologies Inc.(XRM)

Advisors’ Opinion:

  • [By Shane Hupp]

    Media coverage about Xerium Technologies (NYSE:XRM) has trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xerium Technologies earned a news impact score of 0.17 on Accern’s scale. Accern also assigned press coverage about the industrial products company an impact score of 47.7306467260184 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Top 10 Low Price Stocks To Buy For 2019: Carter's, Inc.(CRI)

Advisors’ Opinion:

  • [By Steve Symington]

    Carter’s Inc.(NYSE:CRI)announced first-quarter 2018 results on Thursday morning, detailing a strong performance in spite of the negative impact of the recent bankruptcy of Toy “R” Us on its large wholesale segment. Though shares initially fell almost 5% early on, Carter’s stock recovered to trade modestly higher by this afternoon.

  • [By Joseph Griffin]

    UBS Group initiated coverage on shares of Carter’s (NYSE:CRI) in a research note published on Thursday morning, www.benzinga.com reports. The firm issued a neutral rating and a $114.00 price target on the textile maker’s stock.

  • [By Joseph Griffin]

    Carter’s, Inc. (NYSE:CRI) was the recipient of some unusual options trading activity on Tuesday. Stock investors purchased 2,108 put options on the company. This represents an increase of approximately 1,560% compared to the average daily volume of 127 put options.

  • [By Ethan Ryder]

    Carter’s, Inc. (NYSE:CRI) has earned a consensus recommendation of “Buy” from the fifteen ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $120.27.

  • [By Max Byerly]

    Dimensional Fund Advisors LP grew its holdings in shares of Carter’s, Inc. (NYSE:CRI) by 2.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 450,812 shares of the textile maker’s stock after purchasing an additional 9,306 shares during the period. Dimensional Fund Advisors LP owned approximately 0.96% of Carter’s worth $46,930,000 at the end of the most recent reporting period.

Top 10 Low Price Stocks To Buy For 2019: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Shane Hupp]

    Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT (finance.yahoo.com) Investors Purchase High Volume of Merrimack Pharmaceuticals Call Options (MACK) (americanbankingnews.com) Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 (finance.yahoo.com) Merrimack Pharmaceuticals (MACK) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS (americanbankingnews.com) Merrimack Pharmaceuticals’ (MACK) CEO Richard Peters on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)

    A number of equities analysts have issued reports on MACK shares. Robert W. Baird reiterated a “hold” rating and issued a $12.00 price objective on shares of Merrimack Pharmaceuticals in a report on Thursday, March 15th. Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a report on Wednesday, April 25th.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
    Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
    Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
    Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
    Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
    vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
    Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
    Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
    Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
    GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
    Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market

  • [By Max Byerly]

    Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod (finance.yahoo.com) Merrimack Fails Phase 2 Pancreatic Cancer Study, But Opportunity Remains (seekingalpha.com) Merrimack Pharmaceuticals’ (MACK) “Hold” Rating Reaffirmed at Robert W. Baird (americanbankingnews.com) Merrimack Crashes as Phase II Pancreatic Cancer Study Fails (zacks.com) MM-141 (benzinga.com)

    Several equities analysts have commented on MACK shares. Zacks Investment Research raised Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a research report on Wednesday, April 25th. JPMorgan Chase & Co. downgraded Merrimack Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Monday. Robert W. Baird cut their price objective on Merrimack Pharmaceuticals from $12.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, ValuEngine raised Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.

  • [By Chris Lange]

    Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) shares were absolutely crushed on Monday after the firm gave an update from its midstage pancreatic cancer study. Specifically, the top-line results come from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141 (istiratumab) to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer.

Top 10 Low Price Stocks To Buy For 2019: MPLX LP(MPLX)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    MPLX (NYSE:MPLX) has undergone a significant transformation over the past year and a half. The master limited partnership (MLP) completed several transactions with its oil refining parent Marathon Petroleum (NYSE:MPC), which diversified its midstream portfolio and eliminated costly management fees. Those moves position MPLX to continue growing its rock-solid 6.8%-yielding payout at a healthy clip for the next several years, making it an excellent option for income-seeking investors to consider buying.

  • [By Matthew DiLallo]

    The market gave income-seeking investors a gift in June by selling off units of MPLX (NYSE:MPLX), a midstream master limited partnership (MLP).For the month, the pipeline company inexplicably lost about 5% of its value, pushing it down about 4% for the year. Because of that, it trades at an attractive valuation and now yields 7.3%. Those are just some of the factors that make it a compelling income stock to consider buying this month.

  • [By Tyler Crowe]

    So in this spirit, I thought I would share with you a stock you may want to consider for your own portfolio because it is one I have recently purchased myself: oil and gas logistics player MPLX LP (NYSE:MPLX). Here’s why I think it is a company worthy of investment and the recent change to the business that compelled me to buy this stock.

Top 10 Low Price Stocks To Buy For 2019: Xplore Technologies Corp(XPLR)

Advisors’ Opinion:

  • [By Logan Wallace]

    Xplore Technologies (NASDAQ: XPLR) is one of 25 publicly-traded companies in the “Computer & office equipment” industry, but how does it compare to its peers? We will compare Xplore Technologies to related businesses based on the strength of its dividends, profitability, earnings, risk, valuation, analyst recommendations and institutional ownership.

  • [By Ethan Ryder]

    Xplore Technologies (NASDAQ: XPLR) and Echelon (NASDAQ:ELON) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

  • [By Chris Lange]

    Xplore Technologies Corp. (NASDAQ: XPLR) shares spiked on Thursday after it was announced that the company would be acquired by Zebra Technologies Corp. (NASDAQ: ZBRA). The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2018.

  • [By Logan Wallace]

    A10 Networks (NYSE: ATEN) and Xplore Technologies (NASDAQ:XPLR) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Top 10 Low Price Stocks To Buy For 2019: American Capital Mortgage Investment Corp.(MTGE)

Advisors’ Opinion:

  • [By Max Byerly]

    BidaskClub upgraded shares of MTGE Investment (NASDAQ:MTGE) from a hold rating to a buy rating in a research note published on Thursday.

    A number of other brokerages have also weighed in on MTGE. Keefe, Bruyette & Woods lowered shares of MTGE Investment from an outperform rating to a market perform rating in a research report on Monday, May 7th. Maxim Group lowered shares of MTGE Investment from a buy rating to a hold rating and cut their target price for the company from $21.00 to $19.75 in a research report on Friday, May 4th. Finally, ValuEngine lowered shares of MTGE Investment from a buy rating to a hold rating in a research report on Wednesday, May 2nd.

Top 10 Low Price Stocks To Buy For 2019: Synopsys, Inc.(SNPS)

Advisors’ Opinion:

  • [By Logan Wallace]

    Synopsys (NASDAQ:SNPS) had its price target raised by stock analysts at KeyCorp from $110.00 to $112.00 in a research report issued to clients and investors on Thursday. The firm currently has an “overweight” rating on the semiconductor company’s stock. KeyCorp’s price target would suggest a potential upside of 26.81% from the stock’s current price.

  • [By Logan Wallace]

    These are some of the news headlines that may have effected Accern Sentiment’s analysis:

    Get Synopsys alerts:

    Synopsys, Inc. (SNPS) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com) Free Research Report as Applied Materials Revenues Grew 28.8%; Adjusted EPS Surged 54.4% (finance.yahoo.com) Synopsys IC Validator Certified by Samsung Foundry for 7nm Signoff Physical Verification (prnewswire.com) Synopsys Fusion Technology Enables Lower Power, Smaller Area, and Higher Performance on Samsung Foundry 7LPP Process with EUV (prnewswire.com) Synopsys Announces New Release of LucidShape Software for Automotive Lighting Design and Analysis (finance.yahoo.com)

    A number of equities analysts recently commented on SNPS shares. KeyCorp reaffirmed an “overweight” rating and set a $110.00 price target (up from $106.00) on shares of Synopsys in a research note on Thursday, February 22nd. Royal Bank of Canada reaffirmed a “buy” rating on shares of Synopsys in a research note on Friday, February 23rd. Zacks Investment Research cut shares of Synopsys from a “hold” rating to a “strong sell” rating in a research note on Monday, February 26th. BidaskClub cut shares of Synopsys from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. Finally, ValuEngine raised shares of Synopsys from a “hold” rating to a “buy” rating in a research report on Thursday, April 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. Synopsys presently has an average rating of “Buy” and an average target price of $102.71.

  • [By Joseph Griffin]

    Champlain Investment Partners LLC boosted its position in Synopsys, Inc. (NASDAQ:SNPS) by 3.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 686,287 shares of the semiconductor company’s stock after purchasing an additional 25,685 shares during the period. Champlain Investment Partners LLC owned about 0.46% of Synopsys worth $57,127,000 as of its most recent filing with the SEC.

Top 10 Low Price Stocks To Buy For 2019: B. Riley Financial, Inc.(RILY)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Standard General L.P.’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Standard+General+L.P.

    These are the top 5 holdings of Standard General L.P.National CineMedia Inc (NCMI) – 12,576,000 shares, 60.53% of the total portfolio. New PositionTime Inc (TIME) – 3,181,424 shares, 29.62% of the total portfolio. Turning Point Brands Inc (TPB) – 305,319 shares, 3.58% of the total portfolio. Shares added by 189.90%CafePress Inc (PRSS) – 2,500,000 shares, 3.12% of the total portfolio. New PositionB. Riley Financial Inc (RILY) – 167,736 shares, 1.97% of the total portfoli

  • [By Stephan Byrd]

    Broadridge Financial Solutions (NYSE: BR) and B. Riley Financial (NASDAQ:RILY) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Hot Value Stocks To Buy For 2019

Fred Oltarsh at Options Strategy Network explains that by understanding liquidity, implied and historical volatility, and the skew, options traders are able to build strategies to either mitigate risk or speculate in a manner that provides a reasonable opportunity for successful trading.

The first topic to understand is liquidity. The importance of liquidity is often overlooked in options trading. Whether one is trading standard or binary options, it must be clear to the trader how expensive it is to initiate and liquidate a position. The wider the bid/ask spread as a percentage of the contract value, the costlier it is to trade the particular contract. Ideally, a trader would benefit from the largest contract with the bid/ask spread at a minimum. For those who don’t focus on commissions and slippage, options traders don’t have a chance of making money in the long run.

Hot Value Stocks To Buy For 2019: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Shane Hupp]

    Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT (finance.yahoo.com) Investors Purchase High Volume of Merrimack Pharmaceuticals Call Options (MACK) (americanbankingnews.com) Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 (finance.yahoo.com) Merrimack Pharmaceuticals (MACK) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS (americanbankingnews.com) Merrimack Pharmaceuticals’ (MACK) CEO Richard Peters on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)

    A number of equities analysts have issued reports on MACK shares. Robert W. Baird reiterated a “hold” rating and issued a $12.00 price objective on shares of Merrimack Pharmaceuticals in a report on Thursday, March 15th. Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a report on Wednesday, April 25th.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
    Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
    Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
    Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
    Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
    vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
    Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
    Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
    Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
    GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
    Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market

Hot Value Stocks To Buy For 2019: SodaStream International Ltd.(SODA)

Advisors’ Opinion:

  • [By Stephan Byrd]

    SodaStream (NASDAQ:SODA)‘s stock had its “hold” rating reiterated by stock analysts at Jefferies Group in a research note issued to investors on Wednesday. They currently have a $82.00 price target on the stock. Jefferies Group’s target price suggests a potential downside of 5.87% from the stock’s current price. Jefferies Group also issued estimates for SodaStream’s Q2 2018 earnings at $0.74 EPS, FY2018 earnings at $3.55 EPS, Q1 2019 earnings at $0.88 EPS, Q2 2019 earnings at $0.79 EPS and Q1 2020 earnings at $0.89 EPS.

  • [By Jeremy Bowman]

    I’m talking aboutSodaStream International(NASDAQ:SODA), of course, the Israeli do-it-yourself sparkling water specialist. Shares of SodaStream sold off following the earnings report on Wednesday even though the company once again beat earnings and revenue estimates. Below were the key figures from the first-quarter report.

  • [By Demitrios Kalogeropoulos]

    SodaStream(NASDAQ:SODA) recently announced surprisingly strong first-quarter earnings as sales growth sped up to a 25% pace and profitability improved. The seller of at-home carbonated beverage machines is benefiting from a long-term trend of rising global demand for sparkling water.

  • [By Chris Lange]

    SodaStream International Ltd. (NASDAQ: SODA) reported its fourth-quarter financial results before the markets opened on Wednesday. The company said that it had $1.13 in earnings per share (EPS) on $157.7 million in revenue, which compares with consensus estimates from Thomson Reuters of $0.80 in EPS on revenue of $151.57 million. In the same period of last year, it said it had EPS of $0.71 and $131.8 million in revenue.

Hot Value Stocks To Buy For 2019: ANI Pharmaceuticals, Inc.(ANIP)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Canaccord Genuity set a $82.00 target price on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report released on Tuesday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

best business to buy stock in

NAPLES, Fla. A Naples man said he and his family were discriminated against when a Southwest Airlines employee wouldn’t allow the same-sex couple, their three children and their grandmother to board as a family.

Grant Morse, his husband, Sam Ballachino, their three children and Ballachino’s mother were waiting in the family boarding area at the gate at the Buffalo, N.Y.,airport, ready to catch their flight to Fort Lauderdale on Saturday, when a gate agent quickly approached them.

“Excuse me, this is family boarding only,” Morse said the woman told them. “This is only for family boarding.”

Puzzled, Morse and Ballachino, both 54, looked at each other.

“Well, we are a family and we’re married, and these are our three kids,” Morse said they told the agent. “And that’s our 83-year-old mother that is helping us.”

best business to buy stock in: GRAVITY Co. Ltd.(GRVY)

Advisors’ Opinion:

  • [By Max Byerly]

    ILLEGAL ACTIVITY WARNING: “Gravity (GRVY) Receives Coverage Optimism Score of 0.17” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3382037/gravity-grvy-receives-coverage-optimism-score-of-0-17.html.

  • [By Cooper Creagan]

    For example, if you had taken five minutes to set up a Night Trade on Gravity Co. (Nasdaq: GRVY) in October, you could’ve tripled your money, and then some.

best business to buy stock in: Avnet, Inc.(AVT)

Advisors’ Opinion:

  • [By Stephan Byrd]

    DekaBank Deutsche Girozentrale raised its stake in Avnet (NYSE:AVT) by 763.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,310 shares of the technology company’s stock after purchasing an additional 63,936 shares during the period. DekaBank Deutsche Girozentrale owned about 0.06% of Avnet worth $3,050,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

best business to buy stock in: Insys Therapeutics, Inc.(INSY)

Advisors’ Opinion:

  • [By ]

    Abbvie Inc. (ABBV) , for example, is generally just a pharmaceutical stock. However, the company also marketed Marinol, an FDA-approved synthetic cannabinoid meant to help nausea and vomiting in cancer and AIDS patients. INSYS Therapeutics, Inc. (INSY) is a pharmaceutical company that got approval from the U.S. Drug Enforcement Administration (DEA) for a synthetic cannabis – despite having donated to anti-marijuana advocacy groups in the past.

  • [By Keith Speights]

    In October 2017, I predicted that Insys Therapeutics (NASDAQ:INSY) could be the biggest comeback story of 2018.For a while, it looked like I was on the right track. Insys stock soared in the fourth quarter of 2017. By early January, it was one of the hottest marijuana stocks on the market. Then the momentum evaporated.

  • [By Casey Wilson]

    Others, like cannabis biotech firm Insys Therapeutics Inc. (Nasdaq: INSY), are direct plays in marijuana businesses that offer investors the opportunity for incredibly fast gains.

best business to buy stock in: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
    Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
    Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
    Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
    Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
    vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
    Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
    Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
    Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
    GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
    Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market

  • [By Shane Hupp]

    Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT (finance.yahoo.com) Investors Purchase High Volume of Merrimack Pharmaceuticals Call Options (MACK) (americanbankingnews.com) Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 (finance.yahoo.com) Merrimack Pharmaceuticals (MACK) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS (americanbankingnews.com) Merrimack Pharmaceuticals’ (MACK) CEO Richard Peters on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)

    A number of equities analysts have issued reports on MACK shares. Robert W. Baird reiterated a “hold” rating and issued a $12.00 price objective on shares of Merrimack Pharmaceuticals in a report on Thursday, March 15th. Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a report on Wednesday, April 25th.

best business to buy stock in: Special Opportunities Fund Inc.(SPE)

Advisors’ Opinion:

  • [By Max Byerly]

    Spartan Energy (TSE:SPE) insider Albert Jason Stark sold 21,706 shares of Spartan Energy stock in a transaction dated Tuesday, May 8th. The stock was sold at an average price of C$6.48, for a total transaction of C$140,654.88.

Top High Tech Stocks To Invest In Right Now

1. What’s in store: By all measures, 2017 was a stellar year for the stock market. As we enter a new year, experts are cautiously optimistic that stocks will continue their hot streak in 2018.

Stocks soared last year on huge corporate profits and economic growth. The Dow Jones industrial average shot up by 25%, the S&P 500 grew by 20% and the tech-heavy Nasdaq index outshined them both with a 29% gain.

The rally was also fueled by the promise of the sweeping tax cuts by the Republican-led Congress and President Trump. Over time, those cuts will save corporate America billions.

In 2018, that means corporate earnings will continue to grow. Higher profits should boost the S&P 500 in the new year, said John Lynch, Chief Investment Strategist for LPL Financial.

A strong economy also helped lift stocks this year. Analysts expect the economy to continue growing, albeit at a slower pace than last year.

Wells Fargo (WFC) forecasts the U.S. economy will grow by an average of 2.5% each quarter next year and the year after. That would put the economy on track for its longest expansion in decades — but it would also be one of its weakest expansions since World War II.

Top High Tech Stocks To Invest In Right Now: Armstrong World Industries Inc(AWI)

Advisors’ Opinion:

  • [By Ethan Ryder]

    AptarGroup (NYSE: ATR) and Armstrong World Industries (NYSE:AWI) are both mid-cap industrial products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Top High Tech Stocks To Invest In Right Now: Vanguard FTSE Europe ETF (VGK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Perhaps the largest ETF dedicated to tracking French stocks should be getting more attention. In a year in which ETFs tracking the PIIGS economies are struggling, EWQ has been solid. The France ETF's 2.7 percent year-to-date gain is slightly ahead of the comparable Germany ETF and more than twice as good as the Vanguard FTSE Europe ETF (NYSE: VGK).

  • [By Todd Shriber, ETF Professor]

    Still, there are instances of limited appetite for diversified Europe ETFs, particularly those with significant U.K. exposure. The Vanguard FTSE Europe ETF (NYSE: VGK) hasn't added (or lost) any capital since June 20. That ETF devotes 31.4 percent of its weight to U.K. stocks.

  • [By Tom Aspray, Senior Editor, MoneyShow.com]

    The US stock market is still leading with the Spyder Trust (SPY) up 18.6%, while the European markets (VGK) are now up close to 10% for the year, as they have gotten a nice boost in the past three weeks.

  • [By Todd Shriber, ETF Professor]

    Here is a dichotomy. Global small-caps are performing admirably. The WisdomTree Europe SmallCap Dividend Fund (NYSE: DFE) is an example of a Europe ETF that is defying some unfavorable trends. DFE is down 3.5 percent year-to-date. That sounds bad, but it is far better than what investors have been treated to with diversified, large-cap Europe ETFs. The Vanguard Europe ETF (NYSE: VGK) and the iShares Europe ETF (NYSE: IEV) are down an average of 5.3 percent this year.

Top High Tech Stocks To Invest In Right Now: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap cancer stock Merrimack Pharmaceuticals Inc (NASDAQ: MACK) reported Q1 2017 earnings before the market opened this morning. In early January, Merrimack Pharmaceuticals had announced a definitive asset purchase and sale agreement with Ipsen SA (EPA: IPN; IPSEY) for a transaction valued at up to $1.025 billion (plus up to $33 million in net milestone payments retained by Merrimack pursuant to Merrimack’s exclusive licensing agreement with Shire) under which Merrimack would:

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap cancer stock Merrimack Pharmaceuticals Inc (NASDAQ: MACK) is scheduled for before the market opens on Wednesday (March 1st). In early January, Merrimack Pharmaceuticals reportedadefinitive asset purchase and sale agreement with Ipsen SA (EPA: IPN; IPSEY) for a transaction valued at up to $1.025 billion (plus up to $33 million in net milestone payments retained by Merrimack pursuant to Merrimack’s exclusive licensing agreement with Shire) under which Merrimack will:

  • [By Paul Ausick]

    Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) dropped about 19% on Wednesday to post a new 52-week low of $4.35 against a 52-week high of $9.02 and a Tuesday close of $5.37. Volume of nearly 11 million was more than 3 times the daily average of around 3.4 million. The company said this morning that it is ending its breast cancer treatment study.

  • [By Paul Ausick]

    Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) dropped nearly 11% on Tuesday to post a new 52-week low of $3.30 after closing at $3.67 on Monday. Volume was more than 3 times the daily average of about 3.7 million shares. The stock’s 52-week high is $9.02 The company said Tuesday that it has sold some of its cancer drugs to Ipsen for $1 billion.

Best Clean Energy Stocks To Watch For 2019

Ive been right about Tesla (NASDAQ:TSLA) thus far.

There seem to be only two schools on Tesla. You either love the carmaker, or you hate it with a passion. I fall into the latter category, not because I’m anti clean energy, or opposed to new entries to the auto industry, but because of the grandiose and inefficient management history the company has had under Elon Musk. Ive written often about the competition and general cutthroat nature of the auto industry that Tesla faces. Ive been waiting for some time to see signs of Teslas inability to ramp up car production in a way that justifies its wild stock valuation. And boy howdy have I taken some flak in the comments section.

This week has given me some vindication on my feelings about Tesla. The stock is down on rough news of production complications, and a fading faith in Elon Musks rhetoric, something I said would happen. The valuation is not justified, and cannot be justified when youre selling such a small amount of cars and not turning any profit. I get it that this stock performance is about future potential earnings, but the company is not putting together concrete evidence that it is working toward those types of numbers.

Best Clean Energy Stocks To Watch For 2019: Piedmont Natural Gas Company Inc.(PNY)

Advisors’ Opinion:

  • [By WWW.KIPLINGER.COM]

    Duke also recently has expanded on its natural gas efforts, and will add numerous more natural gas customers when its buy-out of Piedmont Natural Gas Company, Inc. (PNY) goes through.

Best Clean Energy Stocks To Watch For 2019: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap cancer stock Merrimack Pharmaceuticals Inc (NASDAQ: MACK) is scheduled for before the market opens on Wednesday (March 1st). In early January, Merrimack Pharmaceuticals reportedadefinitive asset purchase and sale agreement with Ipsen SA (EPA: IPN; IPSEY) for a transaction valued at up to $1.025 billion (plus up to $33 million in net milestone payments retained by Merrimack pursuant to Merrimack’s exclusive licensing agreement with Shire) under which Merrimack will:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Paul Ausick]

    Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) dropped about 19% on Wednesday to post a new 52-week low of $4.35 against a 52-week high of $9.02 and a Tuesday close of $5.37. Volume of nearly 11 million was more than 3 times the daily average of around 3.4 million. The company said this morning that it is ending its breast cancer treatment study.

Best Clean Energy Stocks To Watch For 2019: MDC Partners Inc.(MDCA)

Advisors’ Opinion:

  • [By Lisa Levin]

    MDC Partners Inc (NASDAQ: MDCA) shares dropped 60 percent to $3.38. MDC Partners reported a Q3 loss of $0.64 per share on revenue of $349.3 million.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on MDC Partners (MDCA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

    Shares of MDC Partners Inc (NASDAQ: MDCA) were down 31 percent to $12.52 after the company posted downbeat quarterly results and lowered its FY16 sales outlook.

  • [By ]

    In particular, Birchenough notes that he has increased confidence in the results due for Aeglea’s lead product candidate pegzilarginase- an enzyme replacement therapy for the treatment of Arginase deficiency and solid tumors.

    MDC Partners (MDCA) Current share price: $7.55

    Keep a close eye on MDC Partners- a fast-growing marketing and communications network. Most interestingly, MDC has just been upgraded by five-star Wells Fargo analyst Peter Stabler. His shift in sentiment comes with a bullish $11 price target (46% upside potential).

Best Clean Energy Stocks To Watch For 2019: PIMCO 25+ Year Zero Coupon US Trs ETF (ZROZ)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Investors with a taste more rate-sensitive bond ETF may want to consider the PIMCO 25 Yr Zro Cupn US Ty Inx Fd ETF (NYSE: ZROZ) and the Vanguard Extended Duration ETF (NYSE: EDV).

best stock investments today

It was nearly two years ago… September 2015.   Stocks had just finished their first 10%-plus correction in years. But I was bullish.   I was preparing to give a speech at the Stansberry Alliance conference. It was titled "Welcome to the Melt Up."   I was worried as I got up on stage. I didn't know how the crowd would react.   I was about to give a speech that was against what everyone in the room believed.   They were all bearish – the speakers, the attendees, you name it. The stock market had fallen in August, and then again in September. These stock market declines had driven investors to an extreme in fear.   "Welcome to the Melt Up" was the opposite of what they wanted to hear. But it turned out to be exactly right…   Stocks have soared over the last two years… They've hit new high after new high.

best stock investments today: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap cancer stock Merrimack Pharmaceuticals Inc (NASDAQ: MACK) is scheduled for before the market opens on Wednesday (March 1st). In early January, Merrimack Pharmaceuticals reportedadefinitive asset purchase and sale agreement with Ipsen SA (EPA: IPN; IPSEY) for a transaction valued at up to $1.025 billion (plus up to $33 million in net milestone payments retained by Merrimack pursuant to Merrimack’s exclusive licensing agreement with Shire) under which Merrimack will:

  • [By Paul Ausick]

    Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) dropped nearly 11% on Tuesday to post a new 52-week low of $3.30 after closing at $3.67 on Monday. Volume was more than 3 times the daily average of about 3.7 million shares. The stock’s 52-week high is $9.02 The company said Tuesday that it has sold some of its cancer drugs to Ipsen for $1 billion.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Peter Graham]

    Small cap cancer stock Merrimack Pharmaceuticals Inc (NASDAQ: MACK) reported Q1 2017 earnings before the market opened this morning. In early January, Merrimack Pharmaceuticals had announced a definitive asset purchase and sale agreement with Ipsen SA (EPA: IPN; IPSEY) for a transaction valued at up to $1.025 billion (plus up to $33 million in net milestone payments retained by Merrimack pursuant to Merrimack’s exclusive licensing agreement with Shire) under which Merrimack would:

  • [By Paul Ausick]

    Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) dropped 9% on Thursday to post a new 52-week low of $3.72 after closing at $4.09 on Wednesday. Volume was more than double the daily average of about 3 million shares. The company had no specific news Thursday.

best stock investments today: Cotiviti Holdings, Inc. (COTV)

Advisors’ Opinion:

  • [By Scott Rubin]

    Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.

best stock investments today: Rackspace Hosting Inc(RAX)

Advisors’ Opinion:

  • [By Monica Gerson]

    Rackspace Hosting, Inc. (NYSE: RAX) reported better-than-expected earnings for the first quarter, but the company missed analysts’ sales estimates. Rackspace shares dropped 7.72 percent to $20.80 in the after-hours trading session.

best stock investments today: Hercules Offshore Inc.(HERO)

Advisors’ Opinion:

  • [By Monica Gerson]

    Hercules Offshore, Inc. (NASDAQ: HERO) is estimated to post a quarterly loss at $1.79 per share on revenue of $68.65 million.

    You On Demand Holdings, Inc. (NASDAQ: YOD) is expected to report its quarterly earnings.

  • [By Lisa Levin]

    Hercules Offshore, Inc. (NASDAQ: HERO) shares dropped 46 percent to $1.05 as the company reported that it has entered into a restructuring support agreement with lenders.

best stock investments today: BAE Systems PLC (BAESY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    BAE Systems (BAESY) and other defense stocks gained on Friday morning after President Donald Trump’s strike on Syria prompted investors to consider the possibility of greater Western involvement in the Syrian conflict.

  • [By SEEKINGALPHA.COM]

    Rheinmetall is currently trading at 15.7x forward earnings and 2.5x book value, a valuation that is closer to its automotive suppliers peers. Compared to its defense peers, its valuation is clearly cheap, as shown in the next table. This shows that Rheinmetall is usually benchmarked against its auto peers, even though 53% of its sales and 41% of operating income have come from its defense unit in the past year.

    P/E P/BV Rheinmetall 15.7 2.5 Continental AG 12.4 2.9 Valeo 13.1 3.6 Brembo (OTC:BRBOF) 17.0 5.2 Leoni (OTC:LNNNY) 13.2 1.9 Auto Peers Average 14.3 3.2 Airbus 24.0 6.8 Leonardo 16.8 2.0 BAE Systems (OTCPK:BAESY) 18.5 5.7 Thales (OTCPK:THLEY) 22.4 4.3 Defense Sector Average 19.2 4.4

    Source: Bloomberg